Search clinical trials for: open label PR OROS methylphenidate

Total 782 results

Janssen-Cilag International NV

Completed

Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

France, Germany, Spain, Switzerland, Netherlands, Portugal, Norway
Janssen-Cilag International NV

Completed

A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder

Attention Deficit/ Hyperactivity Disorder

France, Belgium, Germany, Spain, Switzerland, Denmark, Finland, Netherlands, Norway, Sweden, United Kingdom
Psychiatry Karolinska
Region Stockholm; Ministry of Health and Social Affairs, Sweden

Completed

Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Sweden
Massachusetts General Hospital
National Center for Complementary and Integrative Health (NCCIH); Harvard University

Completed

Pilot Study of Open-label Placebo to Treat Major Depressive Disorder

Major Depressive Disorder

United States
Mayo Clinic

Completed

Efficacy of Penile Traction Therapy Using a Novel Device

Penile Diseases

United States
University of Cincinnati
National Institute on Drug Abuse (NIDA); University of Colorado, Denver

Completed

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

ADHD | Substance Abuse

United States
Pfizer
Pfizer

Recruiting

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease

United States, Nigeria
Universitätsklinikum Hamburg-Eppendorf

Completed

Non-concealed Placebo Treatment for Menopausal Hot Flushes

Hot Flashes

Germany
Leiden University

Completed

Reducing Nocebo Effects on Pressure Pain

Pain | Hyperalgesia

Netherlands
University of Nebraska

Recruiting

ADX-629 Therapy for Sjogren-Larsson Syndrome

Sjogren-Larsson Syndrome

United States
Scion NeuroStim

Enrolling by invitation

STEM-PD Open Label Extension (OLE)

Parkinson Disease | Parkinson's Disease and Parkinsonism

United States
AI Therapeutics, Inc.

Completed

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Oncology

United States
University of California, San Francisco

Recruiting

A Neuroimaging Study of Open-label Placebo in Depressed Adolescents (OLP)

Depression

United States
Massachusetts General Hospital
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

Healthy

United States
Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Georgetown University
Hackensack Meridian Health; Karyopharm Therapeutics Inc

Terminated

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy (SELECT)

Thymoma | Advanced Thymic Epithelial Tumor

United States
University Hospital, Bordeaux

Not yet recruiting

Outpatient Holmium LASER Enucleation of the Prostate: Benefit of MOSES(TM) 2.0 Technology (MOSES)

Benign Prostatic Hypertrophy | Holmium Laser Enucleation of the Prostate
Studio Osteopatico Busto Arsizio

Recruiting

Open-label Placebo in Manual Therapy

Low Back Pain, Recurrent

Italy
University of Maryland, Baltimore

Not yet recruiting

Placebo Impacts Sleep and Pain Modulation in Chronic Headache

Chronic Pain | Headache
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Atopic Dermatitis

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)

Psoriasis

France
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Mechanisms of Desensitization During Peanut Oral Immunotherapy (PnOIT4)

Food Hypersensitivity

United States
Hospital de Egas Moniz

Completed

Open Label Placebo in the Treatment of Low Back Pain

Chronic Low Back Pain

Portugal
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Solid Tumors

United States
University of California, Los Angeles

Enrolling by invitation

In-patient SCC TMS

Major Depressive Disorder

United States
MEI Pharma, Inc.
SCRI Development Innovations, LLC

Completed

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

Solid Tumors

United States
Children's Hospital Medical Center, Cincinnati
National Institute of Mental Health (NIMH)

Completed

Attention Deficit Disorder Medication Response Study

ADHD - Combined Type | ADHD - Inattentive Type

United States
ES Therapeutics Australia Pty Ltd

Recruiting

Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

Drug Resistant Epilepsy

Australia
Menoufia University

Not yet recruiting

Timing of Initiation of Parenteral Nutrition for Critically Ill Children (TPN)

Critical Illness
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
Protagonist Therapeutics, Inc.

Enrolling by invitation

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE)

Polycythemia Vera

United States
Sunovion

Completed

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (SEP-363856)

Schizophrenia

United States
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines

Moderate-severe Glabellar Lines
University of North Carolina, Chapel Hill
The Broad Foundation; Crohn's and Colitis Foundation; OpenBiome

Terminated

Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

Pouchitis

United States
M.D. Anderson Cancer Center

Recruiting

Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers

Fatigue | Metastatic Cancers

United States
Matthew C. Baker

Withdrawn

BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (BAFF/IL-17)

Primary Sjogren's Syndrome

United States
Boston Children's Hospital
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

Epilepsy | Attention Deficit Disorder With Hyperactivity

United States
Vanda Pharmaceuticals

Recruiting

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Gastroparesis | Diabetic Gastroparesis | Idiopathic Gastroparesis

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults

Healthy

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

Healthy Volunteers

United States
Children's Hospital of Philadelphia
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory (CHOP)

Attention Deficit Hyperactivity Disorder

United States
University of Pennsylvania

Terminated

rTMS Pilot for Anxiety

Generalized Anxiety Disorder

United States
University of Arkansas

Completed

Walnut Oral Immunotherapy for Tree Nut Allergy (WOIT)

Tree Nut Allergy

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate

Attention Deficit Hyperactivity Disorder

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

Healthy Volunteers

United States
Alza Corporation, DE, USA

Completed

An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
University of Pennsylvania
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI (DAPET-TBI)

Traumatic Brain Injury | Attention Deficit Disorder | Cognition Disorder

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

Healthy Volunteers

United States
Opsidio, LLC
Innovaderm Research Inc.

Recruiting

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Sanifit Therapeutics S. A.

Completed

Phase 3 Study of SNF472 for Calciphylaxis (Calciphyx)

Calciphylaxis | Calcific Uremic Arteriolopathy

United States, Belgium, United Kingdom, Spain, Germany, Poland

Search clinical trials for: open label PR OROS methylphenidate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations